
Baisios (Beijing) Biotechnology
Gene-edited models and antibody discovery for drug development.
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY20.0m | Series B | |
Total Funding | 000k |
Baisios (Beijing) Biotechnology (Biocytogen) is an international biotechnology company focused on driving new drug research and development through technological innovation. Founded in Beijing in 2009 by Dr. Shen Yuelei, who holds a Ph.D. in immunology, the company leverages his extensive experience in gene editing, animal models, and antibody drug development.
Biocytogen's business is structured around two primary segments: providing preclinical contract research organization (CRO) services and developing its own antibody-based drugs. The company offers thousands of gene-edited animal and cell models, including target humanized and severely immunodeficient mice, which are sold to pharmaceutical companies globally to support preclinical pharmacology and efficacy studies. This business line, branded as 'BioMice,' was a foundational part of the company and has expanded to serve clients in over 20 countries.
A cornerstone of Biocytogen's strategy is the "Project Integrum" (formerly "Thousand Rats and Ten Thousand Antibodies" or "千鼠万抗" plan), a large-scale initiative to discover antibodies for over 1,000 potential drug targets. This project utilizes the company's proprietary RenMice® platform, which consists of fully human antibody mice developed through advanced chromosome engineering. The goal is to create a vast library of therapeutic antibody sequences that can be licensed, co-developed, or transferred to partners worldwide, positioning the company as a source for new drug discovery. Revenue is generated from the sale of animal models, providing preclinical CRO services, and through licensing and collaboration agreements for its antibody assets.
Keywords: antibody discovery, gene editing, preclinical CRO, animal models, humanized mice, drug development, pharmacology services, RenMice platform, Project Integrum, therapeutic antibodies, biopharmaceutical, immunology, oncology, target validation, in-vivo studies, antibody licensing, drug discovery platform, biologics, cell models, antibody drug conjugates